Finasteride and dutasteride are discussed for hair loss, with concerns about their effects on neurosteroids and potential side effects like depression. Alternatives like topical estrogen and lifestyle changes are considered, with varying opinions on mental health and hair regrowth.
The conversation discusses how different factors can stimulate type1 and type 2 isoforms of 5-alphareductase, which are enzymes linked to hair loss. Specific treatments mentioned include oral Dutasteride and topical Finasteride.
GHK-Cu is a potent inhibitor of the type15-alphareductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alphareductase inhibitors. The user previously experienced side effects with 5-alphareductase inhibitors and is considering GHK-Cu as an alternative.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
Beta-sitosterol may inhibit 5-alphareductasetype 2 enzyme, potentially reducing DHT levels and promoting hair growth, similar to finasteride but possibly with fewer side effects. Its effectiveness and side effects compared to other treatments like saw palmetto and finasteride remain uncertain due to limited research.